CV Therapeutics CVTX
-
New Morningstar Analyst Report - Gilead Sciences
… hepatitis B. The acquisitions of Corus Pharma, Myogen, CV Therapeutics , Arresto Biosciences, and Calistoga have broadened this ..... familiar infectious disease territory, including Myogen, CV Therapeutics , and smaller, development-stage acquisitions in oncology …
-
Do Mergers Mean Billions for Biotech?
Michael Becker submits: In March 2009, we asked the question “ Where Might Genentech Investors Redeploy $47 Billion? ” in response to the news that Roche Holding AG ( RHHBY.PK ) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in ...
-
Our Top Biotech Acquisition Picks for 2010
… technology and pipeline candidates . Although less eye - popping , investors who purchased shares of cardiovascular - focused CV Therapeutics would have earned capital appreciation of around 30 % when the firm was swooped up by Gilead GILD less than one month after …
-
New Credit Rating: Gilead Sciences
… adding some uncertainty to the mix for Gilead debtholders . In 2006 , Gilead acquired Myogen , and in 2009 , it acquired CV Therapeutics . The recent failure of darusentan ( a Myogen compound for hypertension ) highlights the risks associated with acquiring …
-
Astellas Enters Hostile Bid for OSI
… Monday has risen above Astellas' $52 per share mark, indicating that the market believes the firm will raise its offer or be outbid by another player (reminiscent of Astellas' failed hostile takeover of CV Therapeutics last year).
-
New Morningstar Analyst Report - Gilead Sciences
… drug Ranexa with the acquisition of CV Therapeutics , it also brings on 170 cardiologist ..... the $1.4 billion acquisition of CV Therapeutics in the spring of 2009 and continuing ..... acquisitions of Corus Pharma, Myogen and CV Therapeutics . Gilead uses a specialized niche …
-
Acquisitions: Big Pharma's Response to Expiring Patents
… purchased Genentech . Most of the deals , however , have been smaller in scale , such as the $ 1 . 4 - billion purchase of CV Therapeutics by Gilead Sciences , the $ 1 . 8 - billion acquisition of the generic - drug business of Austria's Ebewe Pharma by Novartis …
-
More Strength from Gilead in 3Q
… the firm's $3.3 billion cash balance is back at year-end 2008 levels, despite the $1.4 billion acquisition of CV Therapeutics in the spring of 2009 and continuing share buybacks. Several important milestones for Gilead's development pipeline are …
-
CMNWX Principal Capital Appreciation A Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… because they've rallied and reached his estimates of their private market values, including Amylin Pharmaceuticals AMLN and CV Therapeutics . Most of these moves were small--and it has only been a short time since the regional mandate was dropped--but it …
-
Gilead Mixing New HIV Combinations
… announced higher expectations for sales as well as expenses for the full year, factoring in the completed acquisition of CV Therapeutics as well as the near-term costs of the recent collaboration with Tibotec (a subsidiary of Johnson & Johnson JNJ) for …